

Pierre Larochelle

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10715177/pierre-larochelle-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40
papers

2,370
citations

23
h-index

40
g-index

40
ext. papers

2,638
ext. citations

2.8
avg, IF

3.08
L-index

#	Paper	IF	Citations
40	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 569-88	3.8	314
39	The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 549-68	3.8	222
38	The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 485-501	3.8	198
37	The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 528-42	3.8	147
36	The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 270-87	3.8	133
35	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2010 , 26, 249-58	3.8	131
34	Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. <i>Journal of Hypertension</i> , 2006 , 24, 1405-12	1.9	119
33	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 287-98	3.8	97
32	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 583-93	3.8	96
31	The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 415-433.e1-2	3.8	93
30	The atrial natriuretic factor: its physiology and biochemistry. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 1988 , 110, 1-145	2.9	80
29	An emerging relationship between peripheral sympathetic nervous activity and atrial natriuretic factor. <i>Life Sciences</i> , 1987 , 40, 1545-51	6.8	77
28	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 539-50	3.8	76
27	Role of tumor necrosis factor-alpha gene locus in obesity and obesity-associated hypertension in French Canadians. <i>Hypertension</i> , 2000 , 36, 14-9	8.5	76
26	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. <i>Canadian Journal of Cardiology</i> , 2008 , 24, 465-75	3.8	69
25	Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. <i>Journal of Hypertension</i> , 1998 , 16, 1357-1369	1.9	67
24	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. <i>Canadian Journal of Cardiology</i> , 2005 , 21, 657-72	3.8	51

23	The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. <i>Canadian Journal of Cardiology</i> , 2002 , 18, 625-41	3.8	44
22	Hypertension in people with type 2 diabetes: Update on pharmacologic management. <i>Canadian Family Physician</i> , 2011 , 57, 997-1002, e347-53	0.9	35
21	Comparative assessment of four blood pressure measurement methods in hypertensives. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 455-60	3.8	31
20	Unreliability of home blood pressure measurement and the effect of a patient-oriented intervention. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 658-63	3.8	29
19	Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 168-78	2.3	27
18	Hypertension in diabetes: a call to action. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 299-302	3.8	25
17	Single-dose pharmacokinetics of ¹⁴ C-lovastatin in chronic renal failure. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 437-41	6.1	22
16	Effect of metoclopramide on plasma catecholamine release in essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 37, 372-5	6.1	20
15	Responses to tyramine and norepinephrine after imipramine and trazodone. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 24-30	6.1	18
14	The Gap Between Manual and Automated Office Blood Pressure Measurements Results at a Hypertension Clinic. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 653-657	3.8	12
13	Attenuation of autonomic nervous system functions in hypertensive patients at rest and during orthostatic stimulation. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 97-104	2.3	12
12	Basis of false-positive glucagon tests for pheochromocytoma. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 687-94	6.1	11
11	Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. <i>Blood Pressure</i> , 2008 , 17, 170-7 ^{1.7}		10
10	Renal effects of immersion in essential hypertension. Carvedilol Study Group. <i>American Journal of Hypertension</i> , 1994 , 7, 120-8	2.3	10
9	Does QTc interval predict the response to beta-blockers and calcium channel blockers in hypertensives?. <i>Heart Disease (Hagerstown, Md)</i> , 2003 , 5, 244-52		9
8	Treatment of hypertension. <i>Canadian Journal of Diabetes</i> , 2013 , 37 Suppl 1, S117-8	2.1	5
7	Clinical relationships of cyclic GMP. <i>Advances in Pharmacology</i> , 1994 , 26, 305-19	5.7	2
6	The impact of unrecorded readings on the precision and diagnostic performance of home blood pressure monitoring: a statistical study. <i>Journal of Human Hypertension</i> , 2018 , 32, 197-202	2.6	1

5	Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 38, 686-91	6.1	1
4	Traitement de l'hypertension. <i>Canadian Journal of Diabetes</i> , 2013 , 37, S492-S493	2.1	
3	Confirming the critical importance of blood pressure control in people with diabetes. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 594-595	3.8	
2	From Family to Pharmacogenetics. <i>Public Health Genomics</i> , 2000 , 3, 112-115	1.9	
1	Hypertension revisited. <i>Canadian Family Physician</i> , 2012 , 58, 634-6	0.9	